Johnson & Johnson (JNJ)
Fair ValueFundamental
58
Price
$264.74
Market Cap
$655.37B
Part 1 · What the company is worth
Overview
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 19, 2026 with claude-haiku-4-5 — shared with all users
Both are large US-based pharmaceutical groups selling branded prescription medicines to the same hospitals, payers and physicians, with directly overlapping oncology, immunology, vaccine and anti-infective franchises.
AbbVie's Skyrizi and Rinvoq compete head-to-head with Johnson & Johnson's Stelara and Tremfya for the same psoriasis, psoriatic arthritis and inflammatory bowel disease patients.
Merck competes for the same oncology prescriptions, above all in solid tumours and multiple myeloma treatment lines, and for the same public and private vaccine budgets.
Abbott competes directly with Biosense Webster in cardiac electrophysiology catheters and mapping, and with the Vision business in eye-care devices.
Stryker fights DePuy Synthes for the same orthopaedic surgeons and hospital contracts in hip and knee implants, trauma and robotic-assisted surgery.
Medtronic is the closest rival to the MedTech segment, selling competing cardiac ablation, surgical stapling and spine systems to the same hospital purchasing departments worldwide.
Balance Sheet & Liquidity
Revenue
$97.93B
Trailing 12 months (through 6/28/2026)
Net Income
$21.04B
Trailing 12 months (through 6/28/2026)
Free Cash Flow
$19.70B
Total Equity
$81.54B
Total Liabilities
$117.67B
Current Ratio
1.09
Interest Coverage
-
Debt/EBITDA
1.41
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$251.81
Current Price
$264.74
Margin of Safety
-5.1%
Fair Value Range
$186.70 - $316.93
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
30.75
ROE
32.9%
P/B Ratio
7.51
P/FCF
28.68
Gross Margin
67.9%
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
7.5%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (16)
- EPS shows upward trend
- EPS CAGR 6.37%
- Price CAGR 8.71%
- Gross Margin 67.9%
- P/FCF 28.68
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 25.7%
- Analyst Consensus 71% Buy
- Earnings Quality (OCF/NI) 1.31
- Share Dilution 0.0%
- Piotroski F-Score 5/9
Failed (8)
- P/B Ratio 7.51
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 2.7%
- Earnings Surprise avg 0.4%
- PEG Ratio 2.09
- Net Margin Trend 21.5% vs 25.0%
Unavailable (4)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Joaquin Duato | CEO & Chairman | 62 |
| Mr. Joseph James Wolk CPA | Executive VP & CFO | 58 |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine and R&D | 67 |
| Mr. Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 55 |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | 52 |
| Mr. James Swanson | Executive VP & Chief Information Officer | 59 |
| Mr. Ryan Koors | Vice President of Investor Relations | - |
| Mr. Dirk Brinckman | Chief Compliance Officer | - |
| Ms. Elizabeth Forminard J.D. | Executive VP & Chief Legal Officer | 54 |
| Ms. Kristen Blair Mulholland | Executive VP & Chief HR Officer | 58 |
Audit Risk
4
Board Risk
7
Compensation Risk
4
Shareholder Rights Risk
3
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-11
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-23
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-04
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for JNJ, sourced from Markets Gazette.
- 8/2/2026POSITIVEThis Surgical Robot Could Transform the Operating Room
Johnson & Johnson has secured FDA approval for its Ottava surgical robot, marking a significant milestone after years of development and substantial investment. This breakthrough positions J&J to potentially disrupt the established surgical robotics market, currently dominated by early entrants. Investors will be watching closely to see if Ottava can gain market share and challenge competitors, potentially driving future revenue growth for the healthcare giant.
- 7/31/2026NEUTRALWall Street Week | Warsh’s Waiting Game, EU Merger Rules, Robotic Surgeons
Johnson & Johnson is entering the robotic surgery market, a sector experiencing rapid growth. Despite entering the race years after competitors, the company is banking on a distinct strategy to achieve success. This move signifies J&J's strategic diversification into a high-potential medical technology field, aiming to capture market share against established players. Investors will be watching to see if their unique approach can overcome the initial disadvantage and establish a strong foothold in this competitive landscape.
- 6/17/2026NEUTRALJ&J Has No Plans to Enter Obesity Drugs Market, CEO Says
Johnson & Johnson's CEO, Joaquin Duato, has stated the company has no immediate plans to enter the lucrative obesity drug market. This strategic decision shifts focus towards core areas like oncology, differentiating J&J from competitors actively pursuing weight-loss medications. While rivals Eli Lilly and Novo Nordisk have seen success with their obesity drugs, J&J's stance suggests a preference for its established therapeutic areas. Investors will monitor if this focus yields competitive advantages or if J&J misses out on a significant growth opportunity.
- 4/14/2026POSITIVEInside J&J’s Next Blockbuster Drug
Johnson & Johnson's CFO, Joseph Wolk, indicated that the company's new psoriasis pill is on track to become a major revenue driver, having already reached 1,500 patients within days of launch. This positive development, coupled with a robust internal pipeline that allows J&J to bypass large, risky acquisitions, supports the company's decision to raise its financial guidance. Investors can anticipate continued long-term double-digit growth, driven by innovative pharmaceutical products and strategic pipeline management.
- 4/9/2026NEUTRALJohnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson (JNJ) is set to report its Q1 earnings on April 14th, with analysts forecasting $2.67 per share and $23.6 billion in revenue. The company also received FDA approval for its TECNIS PureSee lens, a positive development for its medical devices segment. While the lens approval offers a potential growth catalyst, the upcoming earnings report carries significant weight. Investors will be closely watching revenue figures and forward guidance to gauge the company's performance and outlook amidst evolving market conditions and healthcare sector dynamics.
- 3/6/2026POSITIVEFDA Clears Johnson & Johnson's Multiple Myeloma Combo Drug After Strong Survival Results
The FDA has approved Johnson & Johnson's combination therapy, Tecvayli with Darzalex Faspro, for multiple myeloma. This approval follows strong Phase 3 survival results, indicating significant patient benefit. The clearance marks a key advancement for J&J in the oncology space, bolstering its innovative treatment portfolio. For investors, the green light for new drugs with promising outcomes can lead to increased future revenue and a higher stock valuation, signaling a robust development pipeline.
- 2/27/2026POSITIVE2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash
Johnson & Johnson (JNJ) stands out as a beacon of stability for investors, especially in times of economic uncertainty. Analysis highlights the proven resilience of the pharmaceutical and consumer goods giant, which has historically demonstrated its ability to navigate market turbulence unscathed. This robustness stems from the diversification of its business segments, including pharmaceuticals, medical devices, and consumer health products, ensuring stable cash flows even during recessions. For those seeking a safe haven in a portfolio, J&J's ability to maintain value and generate consistent returns makes it an attractive option, suggesting the stock can be a strategic choice to hold even in the face of a broader market crash.
via Markets Gazette